New Small Molecule Targets 'Undruggable' IGF2BP3: A Breakthrough for Hard-to-Treat Cancers? (2026)

Imagine a breakthrough that shatters the boundaries of what we once thought was impossible in cancer treatment – that's the electrifying promise of small molecule discovery for tackling stubborn cancers. This isn't just another medical update; it's a potential game-changer for patients battling leukemia and other aggressive tumors that have resisted conventional therapies. But here's where it gets controversial: Could targeting proteins long deemed untouchable redefine our approach to 'undruggable' targets, or does this open Pandora's box for unforeseen side effects in treatment? Stick around to dive into the details of this groundbreaking research from UCLA, and you'll see why experts are buzzing with excitement – and some caution.

At the heart of this innovation are scientists from the UCLA Health Jonsson Comprehensive Cancer Center, who've uncovered a tiny compound capable of blocking a notorious cancer-fueling protein that experts once believed couldn't be attacked with medications. This revelation paves the way for an entirely fresh category of therapies aimed at leukemia and other challenging malignancies that don't respond well to existing options.

The star of the show is a small molecule named I3IN-002, which interferes with the protein IGF2BP3's ability to attach to and stabilize RNAs that promote cancerous growth. These RNAs act like accelerators for fierce types of acute leukemia, driving the disease forward relentlessly. According to a study featured in the journal Haematologica, this compound doesn't merely slow down the proliferation of leukemic cells; it actively prompts their death and diminishes the reservoir of leukemia-initiating cells that keep the condition alive and kicking. For beginners wondering how this works, think of IGF2BP3 as a rogue boss in a factory – it manages processes that build and maintain cancer cells. By disrupting its control, I3IN-002 essentially shuts down the assembly line, leading to fewer cancer cells and less aggressive disease.

This endeavor has spanned over a decade, full of persistence and ingenuity. 'We pinpointed IGF2BP3 as a key player in acute leukemias long ago, but lacked the means to strike at it directly,' explains Dr. Dinesh Rao, a professor of pathology and laboratory medicine at UCLA's David Geffen School of Medicine and the study's lead researcher. 'Proving we can now inhibit this protein and derail its role in cancer cells is absolutely thrilling.' As a member of the UCLA Health Jonsson Comprehensive Cancer Center and the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Rao specializes in these complex interactions.

Now, IGF2BP3 is part of a group of RNA-binding proteins that typically operate only during the very early phases of human development, like the blueprint stage before birth. Post-birth, they usually go dormant, but in certain cancers – leukemia, brain cancers, sarcomas, and breast cancers among them – IGF2BP3 reactivates, fueling tumor growth. For decades, drug developers hit a wall because IGF2BP3 doesn't have the usual 'docking sites' or enzyme features that most drugs rely on to attach and work. This made it notoriously hard to target, almost like trying to catch a ghost with a net. And this is the part most people miss: RNA-binding proteins like this aren't your standard cancer foes; they're elusive and lack the clear vulnerabilities that traditional targets have, which has left researchers scratching their heads for years.

'RNA-binding proteins aren't conventional cancer targets,' Rao notes. 'By delving into IGF2BP3's role – specifically how it grabs onto RNA that codes for genes promoting cancer – we crafted a test to block that precise connection.' To illustrate for newcomers, imagine RNA as the messenger carrying instructions for building cancer-promoting tools. IGF2BP3 stabilizes these messages, ensuring the cancer factory runs smoothly. Disrupting that bond is like jamming the communication lines, halting production.

The quest for an inhibitor involved a cutting-edge high-throughput screening process that evaluated nearly 200,000 substances from the UCLA Molecular Screening Shared Resource, overseen by Dr. Robert Damoiseaux. They sought compounds that could prevent IGF2BP3 from latching onto its RNA partners, the core mechanism powering cancer progression. After spotting initial promising candidates, Rao collaborated with UCLA chemistry professor Dr. Neil Garg, whose team examined the compounds' structures and spotted a recurring pattern. This led to the discovery of I3IN-002 as the frontrunner, displaying strong potency at low concentrations and effects that mirrored genetically removing the IGF2BP3 gene entirely. Garg's group then devised an in-house method to produce it, a crucial advancement for further testing.

With I3IN-002 synthesized, the team subjected it to a battery of strict tests to verify its direct impact on IGF2BP3, the cancer-driver they had in their sights. In leukemia cells dependent on IGF2BP3, growth plummeted upon exposure, whereas cells without the protein barely reacted – a clear sign of targeted action. In treated IGF2BP3-expressing cells, the molecule induced apoptosis, the body's programmed cell suicide mechanism, and hindered the protein's RNA binding, a vital tumor-supporting function. It also lowered levels of several oncogenic genes that IGF2BP3 normally protects, highlighting its precision as a potential treatment. For those new to this, apoptosis is like the cell's self-destruct button, triggered when things go wrong, and here it's being flipped on by the compound in cancer cells while sparing healthy ones.

Even in cells where IGF2BP3 was genetically removed, the effects were much milder, providing solid proof that I3IN-002 hits its mark accurately. Further tests, including gene expression analysis, RNA binding studies, thermal shift assays, and drug-stability checks, demonstrated that I3IN-002 physically interacts with IGF2BP3 and modifies its behavior – one of the most solid proofs yet that this 'undruggable' family of RNA-binding proteins can indeed be assaulted with small molecules. But here's where controversy brews: If we can now target these proteins, does that mean we should rush to develop treatments, or could interfering with such fundamental processes in development lead to unexpected health risks? It's a debate worth pondering.

Early trials in mice revealed the compound's effectiveness with noticeable, albeit modest, anti-leukemia results. While the in-vivo impact wasn't as dramatic as desired, Rao points out this is typical for an early prototype. 'The key achievement is demonstrating we can strike the protein and alter its biological role,' he emphasizes. 'This isn't just a win for leukemia studies; it advances the whole domain of RNA-binding proteins in oncology.'

The researchers are now refining I3IN-002 into improved versions – more powerful, more enduring, and better suited for animal and human trials. 'From designing assays to screening drugs, validating hits, and detailed analysis, this represents a pivotal achievement in our lab,' states Dr. Amit Jaiswal, an assistant project scientist in Rao's lab and the study's primary author. Collaborators include Georgia Scherer, Michelle Thaxton, Jacob Sorrentino, Constance Yuen, Milauni Mehta, Gunjan Sharma, Tasha Lin, Tiffany Tran, Amanda Cohen, Robert Damoiseaux, and Neil Garg.

New Small Molecule Targets 'Undruggable' IGF2BP3: A Breakthrough for Hard-to-Treat Cancers? (2026)

References